Plasma Cell Balanitis And Vulvitis: Complete Guide

Rare inflammatory condition of male and female genitalia featuring distinctive red patches and plasma cell histology.

By Sneha Tete, Integrated MA, Certified Relationship Coach

Created on Jun 4, 2026

Rare inflammatory condition of male and female genitalia featuring distinctive red patches and plasma cell histology.

What is plasma cell balanitis/vulvitis?

Plasma cell balanitis, also known as Zoon’s balanitis or balanitis circumscripta plasmacellularis, and its female counterpart plasma cell vulvitis (also called vulvitis circumscripta plasmacellularis or Zoon’s vulvitis), represent a rare, chronic inflammatory dermatosis affecting the genital mucosa. This condition primarily involves the glans penis and prepuce in uncircumcised males, while in females, it targets the vulvar vestibule, labia minora, and introitus. Characterized by well-demarcated, shiny, erythematous patches with a moist, glazed appearance, it is often mistaken for infections or precancerous lesions due to its distinctive ‘cayenne pepper’ speckling.

The aetiology remains idiopathic, though reactive processes to chronic irritation, friction, trauma, or unidentified antigens are implicated. It is not infectious or sexually transmitted, distinguishing it from conditions like candidiasis or herpes. Histologically, a dense plasma cell infiltrate in the dermis (>50% plasma cells) confirms diagnosis, often with epidermal atrophy, vascular dilation, and hemosiderin deposits.

Prevalence is low, affecting middle-aged to elderly individuals predominantly, with males outnumbering females in reported cases. Diagnostic delays average 5 years due to misdiagnosis, leading to unnecessary treatments.

Who gets plasma cell balanitis/vulvitis?

Plasma cell balanitis typically occurs in middle-aged to older uncircumcised men (40–70 years), though younger cases exist. Plasma cell vulvitis affects postmenopausal women most commonly, but can occur at any age. Risk factors include poor genital hygiene, phimosis, chronic moisture under the foreskin, and obesity promoting irritation. No strong genetic or ethnic predisposition is noted, but it is rare globally, with underreporting suspected due to diagnostic challenges.

Males: Glans penis (most common), inner prepuce, coronal sulcus.
Females: Labia minora (45%), vulvar introitus (31%), periurethral area (19%). Labia majora rarely involved due to keratinized epithelium.

Solitary lesions in 53% of cases; multifocal in others. Asymptomatic in some, but most experience discomfort impacting quality of life.

What causes plasma cell balanitis/vulvitis?

The precise cause is unknown. Hypotheses include:

Reactive inflammation: Chronic irritation from friction, urine, smegma, or moisture in the subpreputial space triggers plasma cell response.
Autoimmune or hypersensitivity: Response to mucosal antigens, possibly exacerbated by trauma or infection (though cultures negative).
Vascular factors: Dilation and proliferation contribute to the shiny appearance.

No association with HPV, syphilis, or malignancy. Plasma cells indicate chronicity, not specificity alone—diagnosis requires clinicopathologic correlation.

What are the clinical features of plasma cell balanitis/vulvitis?

Lesions appear as sharp, moist, erythematous macules or plaques with orange-red hue and pinpoint speckling (cayenne pepper spots). Surface is shiny, glazed, velvety; may be erosive or friable. Common sites:

Site	Male (%)	Female (%)
Glans/Prepuce	90	–
Labia minora	–	45
Introitus	–	31
Periurethral	–	19

Symptoms (70–80% cases): burning, stinging, pruritus, dyspareunia, postcoital pain, dysuria. Asymptomatic in 20–30%. Progression slow; may wax/wane.

Diagnosis of plasma cell balanitis/vulvitis

Clinical suspicion prompts biopsy—the gold standard. Exclude infections (swabs for candida, bacteria, HSV, syphilis serology). Dermoscopy shows vascular patterns.

Histopathology:

Predominant plasma cell infiltrate (88–92%) in lamina propria/subepithelium.
Epidermal atrophy (43%), parakeratosis, spongiosis.
Dilated capillaries, hemosiderin (46%), mixed inflammation (55%).
CD138+ plasma cells; rule out extramedullary plasmacytoma via immunohistochemistry.

Differential: candidiasis, lichen planus, erythroplasia Queyrat, Zoon mimics (psoriasis, contact dermatitis).

What is the treatment for plasma cell balanitis/vulvitis?

First-line: ultrapotent topical corticosteroids (clobetasol 0.05% ointment BID, 2–4 weeks, then taper). Response in 64%. Alternative: tacrolimus 0.1% ointment (13% cases, steroid-sparing).

Other options:

Males: Circumcision curative in many (long-term remission).
Females: Avoid surgery; try intralesional steroids, calcineurin inhibitors.
Adjuncts: emollients, hygiene; antibiotics if superinfection (rare).

Refractory cases: CO2 laser, fulguration, platelet-rich plasma (limited evidence). Maintenance therapy often needed; relapse common.

What is the outcome for plasma cell balanitis/vulvitis?

Benign, non-malignant. Symptoms improve with treatment in 70–80%; complete resolution variable. Recurrence post-treatment in 30–50%. Circumcision offers best male prognosis. Long-term follow-up for symptom control and malignancy exclusion.

Prevention of plasma cell balanitis/vulvitis

Daily hygiene, foreskin retraction.
Circumcision consideration in recurrent male cases.
Avoid irritants (soaps, spermicides).

Frequently asked questions

Is plasma cell balanitis/vulvitis cancerous?

No, it is benign inflammatory; no malignant potential reported.

Is it contagious?

No, not infectious or STI-related.

How long does treatment take?

2–12 weeks for initial response; maintenance may be lifelong.

Can it affect both partners?

No, not transmissible.

Does circumcision always cure it in men?

High success rate (70–90%), but not 100%.